Edith A. Perez, MD, discusses the antibody drug conjugate T-DM1 (trastuzumab emtansine; Kadcyla) as a treatment for patients with breast cancer.
Edith A. Perez, MD, professor of medicine, Mayo Clinic, discusses the antibody drug conjugate T-DM1 (trastuzumab emtansine; Kadcyla) as a treatment for patients with breast cancer.
Clinical Pearls:
Roundtable Roundup: Adjuvant Therapy for HR+, HER2- Breast Cancer
June 17th 2025In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a patient with hormone receptor–positive, HER2-negative breast cancer to potentially receive hormonal plus endocrine therapy.
Read More